Indaptus Therapeutics (INDP) Q2 2024 earnings summary

Executive summary

• Lead candidate Decoy20 advanced to weekly dosing in Phase 1 clinical trials for advanced solid tumors, with positive tolerability and plans to accelerate patient enrollment in the second half of 2024.

• Presented new clinical and mechanism of action data at major oncology conferences, highlighting the Decoy platform's unique approach.

• Company remains pre-revenue, funding operations primarily through equity offerings and strategic agreements.

Financial highlights

• Net loss for Q2 2024 was $4.0 million ($0.47 per share), a 24% increase year-over-year; net loss for the first half of 2024 was $7.8 million.

• Operating expenses for Q2 2024 rose 18% to $4.1 million, driven by higher R&D and G&A costs.

• R&D expenses for Q2 2024 were $1.7 million; G&A expenses were $2.4 million.

• Cash and cash equivalents as of June 30, 2024, were $7.3 million, down from $13.4 million at year-end 2023.

• Stockholders’ equity decreased to $6.2 million from $12.1 million at December 31, 2023.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2025, including proceeds from an August 2024 offering.

• Ongoing need for additional capital; inability to secure funding may require reduction or cessation of R&D programs.

• Plans to initiate higher weekly dosing and enroll multiple patients to accelerate trial progress.

• Anticipates increased R&D and G&A expenses as clinical development and hiring continue.